The need for a blueprint emergency plan to avoid a HPAPI crisisHPAPI Safety Strategies Share XThe need for a blueprint emergency plan to avoid a HPAPI crisishttps://pharmaphorum.com/partner-content/the-need-for-a-blueprint-emergency-plan-to-avoid-a-hpapi-crisis/
Bayer begins phase 3 trial testing aflibercept in infant blindnessBayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants. Share XBayer begins phase 3 trial testing aflibercept in infant blindnesshttps://pharmaphorum.com/news/bayer-begins-phase-3-trial-testing-aflibercept-in-infant-blindness/
Working together to embed public involvement in researchAmanda Barrell speaks to the ABPI deputy chief scientific officer Sheuli Porkess and the NIHR’s Simon Denegri at the Share XWorking together to embed public involvement in researchhttps://pharmaphorum.com/views-analysis-patients/abpi-working-together-to-embed-public-involvement-in-research/
Sanofi hands back neurology gene therapy rights to VoyagerSanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as Share XSanofi hands back neurology gene therapy rights to Voyagerhttps://pharmaphorum.com/news/sanofi-hands-back-neurology-gene-therapy-rights-to-voyager/
Addressing global health challenges: the pharmaphorum podcastFor episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to Share XAddressing global health challenges: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/iavi-global-health-challenges/
Registration opens for SMi’s 3rd Annual Ophthalmic Drugs ConferenceInsights into Ophthalmology Share XRegistration opens for SMi’s 3rd Annual Ophthalmic Drugs Conferencehttps://pharmaphorum.com/partner-content/registration-opens-for-smis-3rd-annual-ophthalmic-drugs-conference/
Ophthalmic Drugs ConferenceSMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on Share XOphthalmic Drugs Conferencehttps://pharmaphorum.com/events/ophthalmic-drugs-conference/
The science of prevention‘Prevention’ might be the buzzword of the moment in the pharma industry, but what does it actually mean Share XThe science of preventionhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-science-of-prevention/
VBI craters as investors react to Hep B vaccine dataVBI Vaccines has trumpeted top-line data from a trial pitting its hepatitis B virus (HBV) vaccine candidate against Share XVBI craters as investors react to Hep B vaccine datahttps://pharmaphorum.com/news/vbi-craters-as-investors-react-to-hep-b-vaccine-data/